These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

808 related articles for article (PubMed ID: 11751478)

  • 1. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
    Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP; Zisman A; Bonavida B
    Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells.
    Walczak H; Bouchon A; Stahl H; Krammer PH
    Cancer Res; 2000 Jun; 60(11):3051-7. PubMed ID: 10850456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R; Bedi A
    Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
    Lacour S; Hammann A; Wotawa A; Corcos L; Solary E; Dimanche-Boitrel MT
    Cancer Res; 2001 Feb; 61(4):1645-51. PubMed ID: 11245478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
    Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
    J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis.
    Chawla-Sarkar M; Bae SI; Reu FJ; Jacobs BS; Lindner DJ; Borden EC
    Cell Death Differ; 2004 Aug; 11(8):915-23. PubMed ID: 15118763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
    Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
    Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
    Voelkel-Johnson C; King DL; Norris JS
    Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells.
    Song JH; Song DK; Herlyn M; Petruk KC; Hao C
    Clin Cancer Res; 2003 Sep; 9(11):4255-66. PubMed ID: 14519653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells.
    Mizutani Y; Yoshida O; Miki T; Bonavida B
    Clin Cancer Res; 1999 Sep; 5(9):2605-12. PubMed ID: 10499639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2.
    Frese S; Pirnia F; Miescher D; Krajewski S; Borner MM; Reed JC; Schmid RA
    Oncogene; 2003 Aug; 22(35):5427-35. PubMed ID: 12934102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
    Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumor necrosis factor related apoptosis-inducing ligand induces apoptosis and sensitizes resistant hepatic cancer cells to chemotherapy].
    He SQ; Chen XP; Zhang WG; Wang HP; Wang Q
    Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):456-9. PubMed ID: 15329202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy.
    Bouralexis S; Findlay DM; Atkins GJ; Labrinidis A; Hay S; Evdokiou A
    Br J Cancer; 2003 Jul; 89(1):206-14. PubMed ID: 12838325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
    Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
    Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.